Expert Opinion on Investigational Drugs, Volume 29, Issue 12 (2020)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 29, Issue 12 (2020)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Volume 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Interview

Dr Sandi Dunn illuminates emerging key treatment approaches and companion diagnostics for triple negative breast cancer
Sandra Dunn
Pages: 1309-1312
Published online: 31 Oct 2020
First Page PreviewforDr Sandi Dunn illuminates emerging key treatment approaches and companion diagnostics for triple negative breast cancer | Full Text | PDF (257.8 KB) | EPUB
  • 854 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Editorial

Editorial
Genetic prion disease: opportunities for early therapeutic intervention with rigorous pre-symptomatic trials
Peter Hermann, Jan C. Koch & Inga Zerr
Pages: 1313-1316
Published online: 01 Nov 2020
First Page PreviewforGenetic prion disease: opportunities for early therapeutic intervention with rigorous pre-symptomatic trials | Full Text | References | PDF (1 MB) | EPUB
  • 1618 Views
  • 4 CrossRef citations
  • 0Altmetric
Free Access
Editorial
Batten disease: an expert update on agents in preclinical and clinical trials
Margaux C. Masten, Jonathan W. Mink & Erika F. Augustine
Pages: 1317-1322
Published online: 01 Nov 2020
First Page PreviewforBatten disease: an expert update on agents in preclinical and clinical trials | Full Text | References | PDF (229.5 KB) | EPUB
  • 3513 Views
  • 7 CrossRef citations
  • 0Altmetric
Free Access

Perspective

A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model?
Dario Doller, Anton Bespalov, Rob Miller, Malgorzata Pietraszek & Mikhail Kalinichev
Pages: 1323-1338
Published online: 11 Nov 2020
AbstractforA case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model? | Full Text | References | PDF (993.7 KB) | EPUB
  • 1363 Views
  • 11 CrossRef citations
  • 0Altmetric

Drug Evaluation

Article
Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug
Marwa Sabha, Bernadette C. Siaton & Marc C. Hochberg
Pages: 1339-1346
Published online: 08 Nov 2020
AbstractforLorecivivint, an intra-articular potential disease-modifying osteoarthritis drug | Full Text | References | PDF (341.6 KB) | EPUB
  • 520 Views
  • 10 CrossRef citations
  • 0Altmetric
Article
ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease
Eitan Kerem
Pages: 1347-1354
Published online: 12 Oct 2020
AbstractforELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease | Full Text | References | PDF (1.3 MB) | EPUB
  • 4662 Views
  • 32 CrossRef citations
  • 0Altmetric
Open Access
Article
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)
Si-Yang Liu & Yi-Long Wu
Pages: 1355-1364
Published online: 21 Oct 2020
AbstractforTislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC) | Full Text | References | PDF (368 KB) | EPUB
  • 9871 Views
  • 32 CrossRef citations
  • 0Altmetric
Open Access

Review

The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success
Joost P.H. Drenth & Jörn M. Schattenberg
Pages: 1365-1375
Published online: 27 Oct 2020
AbstractforThe nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success | Full Text | References | PDF (325.3 KB) | EPUB
  • 8742 Views
  • 32 CrossRef citations
  • 0Altmetric
Open Access
Aromatase inhibitors for the treatment of endometriosis: a systematic review about efficacy, safety and early clinical development
Simone Garzon, Antonio Simone Laganà, Fabio Barra, Jvan Casarin, Antonella Cromi, Ricciarda Raffaelli, Stefano Uccella, Massimo Franchi, Fabio Ghezzi & Simone Ferrero
Pages: 1377-1388
Published online: 26 Nov 2020
AbstractforAromatase inhibitors for the treatment of endometriosis: a systematic review about efficacy, safety and early clinical development | Full Text | References | PDF (403.1 KB) | EPUB
  • 541 Views
  • 13 CrossRef citations
  • 0Altmetric
Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors
J. Tanner McMahon, Razan R. Faraj & David Cory Adamson
Pages: 1389-1406
Published online: 26 Oct 2020
AbstractforEmerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors | Full Text | References | PDF (1.9 MB) | EPUB
  • 280 Views
  • 3 CrossRef citations
  • 0Altmetric
Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease
Zeyun Zhou & Christina C. Price
Pages: 1407-1412
Published online: 01 Dec 2020
AbstractforOverview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease | Full Text | References | PDF (761.6 KB) | EPUB
  • 3355 Views
  • 14 CrossRef citations
  • 0Altmetric
Free Access
Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics
Sreenivasa R. Chandana, Hani M. Babiker & Daruka Mahadevan
Pages: 1413-1429
Published online: 06 Nov 2020
AbstractforClinical complexity of utilizing FGFR inhibitors in cancer therapeutics | Full Text | References | PDF (1.7 MB) | EPUB
  • 585 Views
  • 7 CrossRef citations
  • 0Altmetric
Circadian rhythms in diabetic retinopathy: an overview of pathogenesis and investigational drugs
Ashay D. Bhatwadekar & Varun Rameswara
Pages: 1431-1442
Published online: 02 Dec 2020
AbstractforCircadian rhythms in diabetic retinopathy: an overview of pathogenesis and investigational drugs | Full Text | References | PDF (951.5 KB) | EPUB
  • 421 Views
  • 4 CrossRef citations
  • 0Altmetric

Original Research

Article
A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects
Mohammad Farmahini Farahani, Parnian Maghzi, Nazanin Jafari Aryan, Borna Payandemehr, Mayur Soni & Morteza Azhdarzadeh
Pages: 1443-1450
Published online: 12 Oct 2020
AbstractforA randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects | Full Text | References | PDF (1 MB) | EPUB
  • 176 Views
  • 5 CrossRef citations
  • 0Altmetric

Explore articles